▟ Vinebot intrinsic value, daily

← back

WAT Waters Corporation

pharma · valued with opus medium conviction · deep-dived 2026-11-02

HOLD
Intrinsic value$276.33
Price (at call)$462.72
Margin of safety -40.3%
vs market (rating basis) -0.5%

Great chromatography franchise, but even normalized post-BD margins struggle to justify the price.

The story

Waters is a best-in-class franchise in LC/MS chromatography with a large installed base, and roughly half its revenue comes from recurring consumables and service. The BD Biosciences and Diagnostics combination roughly doubles revenue and adds flow cytometry and diagnostics. TTM GAAP figures are distorted by partial-period consolidation, deal costs and acquired-intangible amortization. Underneath, this is a mature, cash-generative business: mid-single-digit organic growth, plus cost synergies that should lift blended margins back toward Waters' historical levels.

Y1 growth moves up from 25% to 30% because TTM revenue of 4.64B still captures only part of BD's year; a full year of the combined company runs near 6.5B. Target margin rises from 26% to 28%: legacy Waters ran 28-30%, BD's lower margins are partly offset by about $345M of targeted cost synergies, and the non-cash amortization of acquired intangibles should not be capitalized into steady-state economics. Sales-to-capital rises from 1.5 to 1.8 because the reported 1.17 is inflated by merger goodwill, while organic growth needs little incremental capital (capex is 0.15B against 0.61B of D&A). Beta, terminal growth and horizon are unchanged.

Value drivers

Revenue growth (Y1)30.0%
Terminal growth3.5%
Forecast horizon8y
Target operating margin28.0%
Years to target margin4
Sales-to-capital1.80
Beta1.00
Failure probability2.0%
Cost of capital (WACC)9.3%
Terminal WACC9.3%

Valuation bridge

PV of explicit FCFF8.15B
PV of terminal value20.36B
Equity value27.13B
÷ shares → per share$276.33

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 6.04B 30.0% 12.7% 653.80M 774.04M -120.25M -110.00M
2 7.62B 26.2% 17.8% 1.16B 879.27M 276.31M 231.22M
3 9.33B 22.4% 22.9% 1.82B 949.50M 869.77M 665.80M
4 11.07B 18.6% 28.0% 2.64B 966.25M 1.67B 1.17B
5 12.71B 14.9% 28.0% 3.03B 913.60M 2.12B 1.36B
6 14.12B 11.1% 28.0% 3.37B 781.95M 2.58B 1.51B
7 15.15B 7.3% 28.0% 3.61B 571.55M 3.04B 1.63B
8 15.68B 3.5% 28.0% 3.74B 294.57M 3.44B 1.69B

Key risks

  • BD integration slippage or synergy shortfall leaves blended margins stuck in the low 20s
  • Pharma and biotech capex cycles, plus China and tariff exposure, weigh on instrument replacement demand
  • Higher leverage and acquired diagnostics businesses with weaker growth dilute the franchise's quality

Catalysts

  • Quarterly prints showing synergy capture and GAAP margins recovering toward the high 20s
  • LC instrument replacement cycle and GLP-1/biologics QA/QC demand driving consumables growth

History

DatePriceIntrinsicMoSRating
2026-11-02$462.72 $276.33 -40.3% HOLD
2026-09-29$442.94 $202.78 -54.2% HOLD
2026-08-26$414.44 $62.59 -84.9% STRONG SELL
2026-07-24$382.41 $75.66 -80.2% STRONG SELL
2026-06-23$357.20 $87.82 -75.4% STRONG SELL